Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Leone Patterson as Executive Vice President, and Chief Business and Financial Officer, effective September 1, 2024."After an extensive search, we are delighted to have Leone Patterson join us at this exciting time as we plan for our next stage of growth and development at Zymeworks," said Kenneth Galbraith, Chair and CEO of Zymeworks. "She brings more than 20 years of public company biotech experience with a proven track record of guiding strategy, finance, operations, and governance through multiple phases of growth, planning

Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Leone Patterson as Executive Vice President, and Chief Business and Financial Officer, effective September 1, 2024. "After an extensive search, we are delighted to have Leone Patterson join us at this exciting time as we plan for our next stage of growth and development at Zymeworks," said Kenneth Galbraith, Chair and CEO of Zymeworks. "She brings more than 20 years of public company biotech experience with a proven track record of guiding strategy, finance, operations, and governance through multiple phases of growth, planning and executing successful financial strategies. Ms. Patterson has the financial leadership qualities to support Zymeworks as we continue to make progress in achieving our 5 by 5 goal of having five novel antibody-drug conjugates or novel T cell engagers in clinical studies by 2026, and progress product candidates from our ADVANCE R&D programs into clinical studies by 2027 and beyond." "I am very pleased to be joining Zymeworks as the Company plans for many important milestones in the months and years ahead. I look forward to working collaboratively with the experienced leadership team in maximizing the value of the rapidly expanding pipeline and addressing many critical areas of unmet medical needs for patients with difficult-to-treat cancers and other serious diseases," said Ms. Patterson. Prior to joining Zymeworks, Ms. Patterson served as Chief Financial and Business Officer at Tenaya Therapeutics where she led corporate finance, investor relations, corporate communications, strategy and business development teams as well as other operational functions. She previously held leadership positions at Adverum Biotechnologies including Chief Financial Officer, President, Chief Executive Officer and Director. She also has held senior finance positions at Diadexus, Transcept, Exelixis, Novartis, and Chiron. Earlier in her career she worked in the audit practice of KPMG. Ms. Patterson currently serves on the board of directors of Nkarta, Inc. and Oxford Biomedica, both publicly-held companies. She earned a B.S. in business administration and accounting from Chapman University and an executive MBA from St. Marys College. Ms. Patterson is also a Certified Public Accountant (inactive status). Ms. Pattersons appointment builds on the Companys continued focus on strengthening its leadership in the biopharmaceutical industry and expanding its pipeline of pharmaceutical candidates with the potential to make a significant difference in the lives of patients around the world with difficult-to-treat cancers and other diseases. She will be responsible for assisting with the development of Zymeworks long-term financial strategy, providing leadership surrounding financing and capital strategies and supporting strategic business decisions. She will be based in the new Zymeworks location in Redwood City, California. About Zymeworks Inc. Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Companys complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Companys proprietary Azymetric technology. Zymeworks has entered into separate agreements with BeiGene, Ltd.and follow @ZymeworksIncon X. Cautionary Note Regarding Forward-Looking Statements This press release includes "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Ms. Pattersons anticipated appointment date; Ms. Pattersons expected contributions to Zymeworks strategic goals; potential therapeutic effects and commercial potential of zanidatamab and Zymeworks other product candidates; Zymeworks clinical development of its product candidates and enrollment in its clinical trials; the ability to advance product candidates into later stages of development; and other information that is not historical information. When used herein, words such as "plan", "believe", "expect", "may", "continue", "anticipate", "potential", "will", "progress", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: clinical trials may not demonstrate safety and efficacy of any of Zymeworks or its collaborators product candidates; any of Zymeworks or its partners product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions; and the factors described under "Risk Factors" in Zymeworks quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedar.com). Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events. Contacts: Investor Inquiries: Shrinal Inamdar Director, Investor Relations ?? Media Inquiries: Diana Papove Senior Director, Corporate Communications

Tenaya Therapeutics

Zymeworks

Zymeworks Inc.: Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

Biotechnology & Medical Research

Biotechnology & Medical Research (NEC)

Software

Enterprise Software

Public Sector & Health Tech

Security & Infrastructure Software

Data Science

Zymeworks Appoints Leone Patterson as Chief Business & Financial Officer

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced changes to its Research leadership team, including new appointments to the companys Scientific Advisory Board (SAB). Kathy Ivey, Ph.D., Vice President of Gene Therapy Research, will be promoted to Senior Vice President, Research, with responsibility for all Tenayas non-clinical research and discovery work. Timothy Hoey, Ph.D., who has served as Tenayas Chief Scientific Officer since 2017, will step down from his role. Dr. Hoey will remain with the Company in an advisory capacity, including joining Tenayas Scientific Advisory Board (SAB) and serving as a consultant to Tenayas Science & Technology Committee. In addition, Barry J. Byrne, M.D., Ph.D., Professor and Associate Chair of Pediatrics, Molecular Genetics & Microbiology Director, Powell Gene Therapy Center, University of Florida School of Medicine, has also been appointed to Tenayas SAB. "Kathy was instrumental in Tenayas formation in 2016 and has led our genetic medicines discovery efforts since day one as Tenayas first full-time employee. She currently leads our gene therapy, gene editing and regenerative medicine programs, as well as efforts to discover and design novel AAV capsids, promoters, and other regulatory elements," said Faraz Ali, Chief Executive Officer of Tenaya Therapeutics. "This is a well-deserved promotion, and we look forward to Kathys continued leadership to successfully guide our science in pursuit of our mission to improve the lives of those with heart disease." "We are grateful to Tim for seven incredible years of scientific leadership and progress at Tenaya, without which we would not be who we are today. His leadership was fundamental in building a strong research team, establishing differentiated capabilities, creating a deep and diverse pipeline, and moving three product candidates into the clinic. Were thrilled that Tims expertise will remain available to Tenaya as he transitions to an advisory role, and we wish him all the best in his future endeavors," added Mr. Ali. "We are also thrilled to welcome Dr. Byrne to Tenayas SAB. His expertise as a pediatric cardiologist and extensive clinical research experience specific to genetic therapies provides him with unique insights into our work on gene therapy and gene editing in cardiomyopathies that affect young people." Separately, Tenaya also announced that Jin-Long Chen, Ph.D., is stepping down from the companys Board of Directors following more than seven years of service to focus on other commitments, including his role as Managing Partner of TCG Labs Soleil. "On behalf of the Tenaya Board of Directors, Id like to convey our appreciation for Dr. Chens many contributions during his tenure as a Board member," said David Goeddel, Ph.D., Chair of Tenayas Board of Directors and Managing Partner at The Column Group. Kathy Ivey, Ph.D. Kathy Ivey brings nearly 25 years of experience in the discovery of transformative product candidates for heart disease. For the past several years, she has overseen the discovery and preclinical testing efforts that resulted in Tenayas TN-201 and TN-401 gene therapy product candidates. Dr. Ivey has also led the companys capsid engineering efforts to create novel adeno-associated capsids with greater selectivity to deliver genetic medicines with the potential to prevent or reverse specific forms of cardiac disease. In addition, she has been responsible for much of Tenayas most cutting-edge endeavors, including early-stage gene editing and cardiac regeneration programs. Previously, Dr. Ivey was a Staff Researcher at The Gladstone Institutes where she directed the Gladstone Stem Cell Core and worked with Tenayas scientific co-founder, Deepak Srivastava, MD., and aided in Tenayas formation. Dr. Ivey is trained in Molecular and Cell Biology and holds a B.S. from Texas A&M University and Ph.D. from UT Southwestern Medical Center where she completed her thesis work within the Molecular Biology Department chaired by Tenaya co-founder, Eric Olson, Ph.D. Barry J. Byrne, M.D., Ph.D. Dr. Barry Byrne is a renowned clinical scientist specializing in the development of medicines for inherited muscle diseases. Since joining the University of Florida in 1997, he has served in a variety of clinical, research and educational roles, and is now the Director of the Powell Gene Therapy Center. As a pediatric cardiologist, Dr. Byrnes focus is on conditions that lead to skeletal muscle weakness, cardiac dysfunction and respiratory dysfunction. His research team has contributed to the advancement of genetic therapies for Pompe, Duchennes Muscular Dystrophy, Friedreichs ataxia, and other neuromuscular conditions. Dr. Byrne earned his M.D. and Ph.D. in Microbiology and Immunology at the University of Illinois after obtaining a B.S. degree in Chemistry from Denison University. He completed his pediatric residency, cardiology fellowship training and post-doctoral training in Biological Chemistry at Johns Hopkins University. He is a board-certified pediatric cardiologist with greater than 330 publications. About Tenaya Therapeutics Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Leveraging its integrated and interrelated Gene Therapy, Cellular Regeneration and Precision Medicine platforms and proprietary core capabilities, the company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. Tenayas most advanced candidates include TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301, a small molecule HDAC6 inhibitor being initially developed for heart failure with preserved ejection fraction (HFpEF). Tenaya also has multiple early-stage programs progressing through preclinical development. For more information, visit www.tenayatherapeutics.com. Contacts Michelle Corral VP, Corporate Communications and Investor Relations IR@tenayathera.com Investors Anne-Marie Fields Precision AQ Annemarie.fields@precisionaq.com Media Wendy Ryan Ten Bridge Communications wendy@tenbridgecommunications.com

Tenaya Therapeutics Announces Leadership Changes

Promotion

Technology

Research & Development

Senior Vice President, Research

Vice President (VP)

Kathy is currently a Tenaya Therapeutics for 7 years and 9 months, having joined in February 2022 as a Director of Gene Therapy Biology. Prior to this, she worked at Gladstone Institutes from June 2005 to October 2016, starting as a Research Scientist and progressing to roles including Staff Research Investigator and Stem Cell Core Director. Kathy also serves as an Adjunct Assistant Professor at UCSF. She holds a PhD in Biomedical Science from UT Southwestern Medical Center (1999 - 2004).

Hire

Scientific Advisory Board

Barry J. Byrne, M.D., Ph.D. is a renowned clinical scientist specializing in genetic therapies for inherited muscle diseases. He currently serves as the Director of the Powell Gene Therapy Center at the University of Florida School of Medicine. Dr. Byrnes work focuses on conditions leading to skeletal muscle weakness, cardiac dysfunction, and respiratory dysfunction. His research has contributed to advancements in genetic therapies for Pompe disease, Duchennes Muscular Dystrophy, Friedreichs ataxia, and other neuromuscular conditions. Dr. Byrne earned his M.D. and Ph.D. in Microbiology and Immunology from the University of Illinois and completed his pediatric residency, cardiology fellowship, and post-doctoral training in Biological Chemistry at Johns Hopkins University. He has published over 330 scientific papers and is a board-certified pediatric cardiologist. Recently, he was appointed to Tenaya Therapeutics Scientific Advisory Board, bringing his extensive expertise in genetic therapies and pediatric cardiology to the company.

Tim is currently the Chief Scientific Officer at Tenaya Therapeutics, a position he has held since August 2017. Prior to this role, he served as the Sr. Vice President of Cancer Biology/Co-CSO at OncoMed Pharmaceuticals from 2005 to 2017. Before his time at OncoMed Pharmaceuticals, Tim was a Scientist/Director at Tularik/Amgen from 1993 to 2005. He began his career as a Postdoctoral Fellow at the University of California, Berkeley from 1989 to 1993.

Tim holds a PhD in Biological Sciences from Columbia University (1984 - 1989) and a BS in Biology from the University of Michigan (1976 - 1980).

Zymeworks Appoints Leone Patterson as Chief Business & Financial Officer

latest related moves